HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Avon gets go-ahead from China

This article was originally published in The Rose Sheet

Executive Summary

Chinese Ministry of Commerce and State Administration for Industry and Commerce approve Avon as first company to test direct selling in Beijing, Tianjin and Guangdong provinces this month, firm announces April 8. Test is a "preparation for a successful implementation" of direct selling legislation currently under development by the government, according to Avon. Firm, which views China as a significant growth opportunity, lobbied the Chinese government to end the direct sales ban, instituted in 1998. Avon received verbal permission last year to roll out a direct-sell test program, and has been awaiting written approval (1"The Rose Sheet" Aug. 2, 2004, In Brief). Other direct sellers looking to enter China include Nu Skin, which plans to expand its presence in the region once the ban is formally lifted...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS012955

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel